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ERK1/2We previously showed that Bcl-xL and Mcl-1 cooperatively protect platinum-resistant ovarian cancer
cells from apoptosis. Here we assessed the anticancer potential of combining ABT-737-induced inhibition
of Bcl-xL with Mcl-1 inhibition via PI3K/Akt/mTOR pathway disruption using NVP-BEZ235. NVP-BEZ235
inhibited cell proliferation without inducing apoptosis. It strongly repressed Mcl-1 expression and
induced Puma expression in both cell lines tested while differentially modulating Bim between the
two. Interestingly, NVP-BEZ235 efﬁciently sensitized ovarian carcinoma cells to ABT-737, provided that
Bim expression was induced. Moreover, inhibiting the ERK1/2 pathway restored Bim expression and sen-
sitized low Bim-expressing cancer cells to the BEZ235/ABT-737 treatment.
 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction anti-apoptotic members are frequently found in cancer cells. TheseOvarian cancers represent the leading cause of death from
gynaecologic malignancies and the ﬁfth most frequent cause of
cancer death of women in the United States [1]. The majority of pa-
tients present with advanced disease and their treatment consists
of debulking surgery followed by platinum/taxane-based chemo-
therapy [2]. Despite a high response rate to this ﬁrst-line therapy,
most patients relapse and develop chemoresistance. Therefore, the
5-year survival rate of patients with advanced ovarian cancer is
very poor, currently below 30%. The identiﬁcation of novel thera-
peutic strategies thus represents an important goal for the clinical
management of such cancers.
Upregulation of anti-apoptotic members of the Bcl-2 family and
subsequent alteration of the balance between pro- andanti-apoptotic proteins counteract the death signals induced by
oncogenic stress in cancer cells by sequestrating the pro-apoptotic
members of the Bcl-2 family [3]. Cancer cells are thus qualiﬁed as
‘‘primed for death’’ and may be addicted to Bcl-2 family anti-apop-
totic proteins for their survival [3]. Exploiting this addiction
appears as an attractive strategy for anticancer therapy. In line
with this notion, we previously showed that concomitant inhibi-
tion of Bcl-xL and Mcl-1 was sufﬁcient to induce massive apoptosis
in resistant ovarian carcinoma cells, even in the absence of chemo-
therapy [4–6]. Bcl-xL and Mcl-1 proteins thus cooperate to protect
resistant ovarian cancer cells from apoptosis and together consti-
tute a strong molecular ‘‘bolt’’ the elimination of which is sufﬁcient
to allow apoptotic cell death.
One available pharmacological approach to inhibit anti-apopto-
tic Bcl-2 family members and thereby trigger apoptosis consists in
disrupting their interactions with their pro-apoptotic partners
using BH3-mimetic molecules [7]. ABT-737 is one of the most po-
tent and speciﬁc BH3-mimetic compounds [8] and its orally
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phase I and II clinical evaluation in various tumour types [9,10].
ABT-737 binds with high afﬁnity to Bcl-2, Bcl-xL and Bcl-w and
antagonizes their anti-apoptotic function [8]. It has been shown
to induce apoptosis in several cellular models [8,11–13] and to
sensitize cancer cells to chemotherapeutic agents such as platinum
compounds [5,14]. However, ABT-737 is unable to inhibit the
activity of Mcl-1, the expression of which hinders ABT-737-in-
duced apoptosis in various cancer types [12,15–18] including ovar-
ian cancers [5]. Moreover, ABT-737 is able to stabilize Mcl-1 in
various contexts [5,18,19]. Therefore, Mcl-1 inhibition represents
an important obstacle to overcome before the successful imple-
mentation of Bcl-xL-targeting therapies, including the use of
BH3-mimetic molecules.
Inhibiting Mcl-1 activity can be achieved either by inhibiting
Mcl-1 expression or by promoting the expression/activation of its
endogenous inhibitors, the pro-apoptotic BH3-only proteins. In-
deed, tBid, Bim, Puma and Noxa BH3-only proteins compete
against the pro-apoptotic proteins Bak and Bax for their binding
to Mcl-1 [20]. Pharmacological inhibition of signaling pathways
that promote Mcl-1 and inhibit BH3-only proteins could therefore
be efﬁcient to sensitize ovarian cancer cells to ABT-737. In this con-
text, the PI3K/Akt/mTOR pathway appears as an attractive target.
First, it promotes Mcl-1 expression at different levels: (i) transcrip-
tional, via the activation of CREB transcription factor [21]; (ii)
translational, via the activation of mTORC1 and subsequent phos-
phorylation of 4E-BP1 [22,23]; and (iii) post-translational, through
decreased proteasomal degradation due to repression of GSK3-in-
duced phosphorylation [24]. Moreover, the PI3K/Akt/mTOR path-
way can also modulate Mcl-1 activity by regulating Bim
expression and phosphorylation [25,26] and Puma expression
[27]. Second, this pathway has been demonstrated to interact coor-
dinately with Bcl-2 and/or Bcl-xL to promote survival of cancer
cells [28,29]. Finally, the PI3K/Akt/mTOR pathway has been re-
ported to be one of the most deregulated signaling pathways in
many tumours including ovarian tumours [30].
Among the PI3K/Akt/mTOR inhibitors, PI3K/mTOR dual inhibi-
tors are extremely useful to target in full the pathway both up-
stream and downstream, thus avoiding undesirable feedback
regulations that are described to occur with rapalogs [31].
NVP-BEZ235 (hereafter referred to as BEZ235) is an imidazo[4,5-
c]quinoline derivative that inhibits both pan-class I PI3K and mTOR
kinase (in mTORC1 and mTORC2 complexes) by binding reversibly
and competitively to the ATP-binding cleft of these enzymes [32].
It shows antiproliferative and antitumor activity in vitro and in vivo
in a great variety of cancer types [32–36], and is currently being
tested in phase I and II clinical trials. Moreover, a few studies have
provided evidence for the efﬁcacy of BEZ235 in ovarian cancer
cells, showing it to efﬁciently decrease cell proliferation in vitro
and tumour growth in vivo [37,38], reduce cell migration in vitro
[38] and display synergistic effect when combined with platinum
derivatives [37,38] or taxanes [37].
However, the impact of PI3K/Akt/mTOR pathway modulation by
BEZ235 on the expression of Mcl-1 and its partners has never been
explored in ovarian cancers. We thereby studied the effect of
BEZ235 on the expression of both Mcl-1 and BH3-only proteins
Noxa, Puma and Bim in chemoresistant IGROV1-R10 and SKOV3
cell lines and its ability to sensitize these cells to Bcl-xL-targeting
strategies.
Materials and methods
Cell culture and treatment
The human ovarian carcinoma cell lines SKOV3, IGROV1-R10 and IGROV1 were
used. SKOV3 and IGROV1-R10 cells were platinum-resistant, whereas IGROV1 cells
were platinum-sensitive. SKOV3 was obtained from American Type CultureCollection (Manassas, USA) and IGROV1-R10 was established as previously de-
scribed [39] from the IGROV1 cell line, kindly provided by Dr. Jean Bénard (Institut
Gustave Roussy, Villejuif, France). All of the cell lines were grown in RPMI Medium
1640 + Glutamax™ (Gibco, Paisley, UK) supplemented with 10% Foetal Bovine Ser-
um (Gibco) and 33 mM sodium bicarbonate (Gibco) and were maintained in a 5%
CO2 humidiﬁed atmosphere at 37 C.
The PI3K/mTOR dual inhibitors BEZ235 and NVP-BGT226 (hereafter referred to
as BGT226), the MEK inhibitor CI-1040 and ABT-737 were purchased from Selleck
Chemicals (Munich, Germany). Stock solutions were prepared in DMSO at 5 mM,
5 mM, 25 mM and 20 mM respectively and stored according to the manufacturer’s
instructions. A total of 5 x 105 cells were plated in 25 cm2 ﬂasks and treated 24 h
later, when cells had reached their exponential growth phase.siRNA synthesis and transfection
All siRNAs used in this study were chemically synthesised by Eurogentec (Liege,
Belgium) and were received as annealed oligonucleotides. Sequences were as fol-
lows: Bcl-xL siRNA antisense (denoted siBcl-xL, targeting speciﬁcally the Bcl-xL
mRNA but not the Bcl-xS mRNA), 50-auuggugagucggaucgcatt-30; Bim siRNA anti-
sense (denoted siBim), 50-uaacagucguaagauaacctt-30; and Puma siRNA antisense
(denoted siPuma), 50-uauacaguaucuuacaggctt-30 . Control siRNA (noted siCtrl) was
purchased from Eurogentec (Eurogentec Negative Control SiRNA).
A total of 2.5 x 105 SKOV3 cells or 3.5 x 105 IGROV1-R10 cells were plated in
25 cm2 ﬂasks and transfected 24 h later, when they had reached their exponential
growth phase. Brieﬂy, the transfecting INTERFERin™ reagent (Polyplus Transfec-
tion, Strasbourg, France) was added to siRNA (20 nM) diluted in Opti-MEM Re-
duced–Serum Medium (Gibco). Complex formation was allowed to proceed for
15 min at RT before application to cells.Proliferation analysis
Cell number and viability were estimated at various times after the beginning of
treatment by a semi-automated image-based cell analyzer (Cedex XS Analyzer,
Roche Applied Science, Meylan, France) using the Trypan blue exclusion method.RNA extraction and real-time quantitative reverse transcription PCR (qRT-PCR)
Total RNAs were extracted using the TRIzol reagent (Invitrogen, Life Technol-
ogies, Saint Aubin, France) and reverse transcribed using Omniscript reverse trans-
criptase (Qiagen,Courtaboeurf, France) with random primers according to the
manufacturer’s instructions. The obtained cDNA (25 ng) were combined with a Taq-
Man Universal Master Mix II (Applied Biosystems, Foster City, CA, USA). Primers
and TaqMan probe were then added in a 20 ml ﬁnal reaction volume. Primer and
probe sequences for real-time detection of Bim mRNA (assay ID
#Hs00708019_s1) and endogenous control gene GAPDH mRNA (assay
ID#Hs99999905_m1) were purchased from Applied Biosystems. All PCR ampliﬁca-
tion reactions were carried out in triplicate and the analyses were made on an Ap-
plied ABI Prism 7500 Fast PCR system (Applied Biosystems). Bim transcripts were
quantiﬁed relative to GAPDH and normalized to control untreated cells by the com-
parative 2DDct method.Extraction of proteins and western-blot analysis
Proteins were extracted as follows: cells were rinsed with ice-cold PBS, lysed in
50 mM Tris-HCl (pH 8), 150 mM NaCl, 1% Nonidet P-40, 5 mM EDTA, 10 mM NaF,
4 mM PMSF, 2 mM aprotinin, 10 mM NaPPi, 1 mM Na3VO4 and a complete mini
mixture of protease inhibitors (Roche Applied Science) and incubated on ice for
30 min. Lysates were collected after centrifugation (13,000 g, 10 min, 4 C) and pro-
tein concentrations were determined using the Bradford assay (Bio-Rad, Hercules,
USA). Equal amounts of proteins (30 lg) were separated by SDS-PAGE on a 4–15%
gradient polyacrylamide Mini-PROTEAN TGX™ precast gel (Bio-Rad) and trans-
ferred to PVDF membranes (Bio-Rad). Membranes were blocked for 2 h at RT with
5% (w/v) non-fat dry milk in TBS with 0.05% (v/v) Tween20 (T-TBS). Membranes
were then incubated overnight at 4 C with the primary antibodies. P-Akt
(Ser473), P-Akt (Thr308), Akt, P-4E-BP1 (Thr70), 4E-BP1, P-p70S6 K (Thr389),
p70S6 K, P-ERK1/2 (Thr202/Tyr204), ERK1/2, caspase 3, PARP, Bcl-xL (54H6), Puma
(D30C10) and Bim antibodies were purchased from Cell Signaling (Beverly, MA,
USA), Mcl-1 (S19) antibody from Santa–Cruz Biotechnology (Dallas, TX, USA), Noxa
antibody from Calbiochem (Darmstadt, Germany), Bcl-2 antibody from DAKO
(Glostrup, Denmark), b-actin antibody from Millipore (Billerica, MA, USA) and a-
tubulin antibody from Sigma (Saint–Quentin Fallavier, France). Membranes were
then incubated for 1 h with the appropriate horseradish peroxidase-conjugated
anti-rabbit (Cell Signaling or Amersham GE Healthcare Life Sciences, Buckingham-
shire, UK) or anti-mouse (Amersham) secondary antibodies. Signals were revealed
by electrochemoluminescence (ECL, Amersham GE Healthcare Life Sciences) using
the ImageQuant LAS 4000 Series (GE Healthcare Life Sciences, Velizy–Villacoublay,
France), and then quantiﬁed by pixel densitometry using the ImageJ software.
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Total cell lysates were prepared in Lysis Buffer [30 mM HEPES, 100 mM KCl,
20 mM NaCl, 2 mM MgCl2, 5% glycerol, 2% heptanetriol, 0.5% laurylmaltoside,
5 lM GDP, 1 lM microcystine, 1 mM sodium orthovanadate Na3VO4 and protease
inhibitors (Complete, Roche)]. After 30 min of pre-clearing at 4 C, proteins (500 lg)
were immunoprecipitated with anti-Bcl-xL antibody (Abcam, Cambridge, MA, USA)
and captured by incubation with a 50% slurry of protein G-Sepharose (GE Health-
care Life Sciences) overnight at 4 C under gentle agitation. Immunoprecipitates
were then recovered by centrifugation and washed three times in Lysis Buffer.
Immunoprecipitates, supernatant (18 lg) and total cell extracts (18 lg) were sepa-
rated by SDS-PAGE and the expression of Bim and Bcl-xL proteins was analyzed as
described in the previous section.
Nuclear staining with 40 ,6-diamidino-2-phenylindole (DAPI)
Both detached and adherent cells were pooled, collected on a polylysine-coated
glass slide by cytospin centrifugation and ﬁxed with a solution of ethanol/chloro-
form/acetic acid (6:3:1). The preparations were then incubated with 1 lg/ml DAPI
(Boehringer Mannheim, Germany) in water at RT. After 30 min, they were exten-
sively washed in ultra pure water and mounted in Mowiol (Calbiochem) under a
coverslip.
Analysis of DNA cellular content by ﬂow cytometry
Both detached and adherent cells were pooled, washed with 1X PBS and ﬁxed
with 70% ethanol. Cells were then centrifuged at 4000 rpm for 5 min and incubated
for 30 min at 37 C in PBS to allow the release of low-molecular weight DNA, char-
acteristic of apoptotic cells. Cell pellets were stained with propidium iodide (PI)
using the DNA Prep Coulter Reagent Kit (Beckman–Coulter, Villepinte, France).
Samples were thereafter analyzed using a Gallios ﬂow cytometer (Beckman–Coul-
ter) and cell cycle distribution was determined using Kaluza acquisition software
(Beckman–Coulter).
Real-time cell analysis (xCELLigence)
Treatment-mediated cytotoxicity was monitored with the Real-Time Cell Ana-
lyzer multi-plate (RTCA MP) Instrument, using the xCELLigence System (Roche Ap-
plied Science, Mannheim, Germany). This system monitors cellular events in real
time by measuring electrical impedance across interdigitated micro-electrodes
integrated on the bottom of tissue culture E-plates (96-well View, Roche). The in-
crease in the number and size of cells attached to the electrode sensors leads to in-
creased impedance, based on which the Cell Index values are derived and displayed
in the plot. This index thus reﬂects changes in cell viability as described by Ke et al.
[40]. Brieﬂy, 7 x 103 IGROV1-R10 cells/per well were plated in an E-Plate View 96
and placed onto the RTCA MP located inside a tissue culture incubator. Cells were
left to grow for 24 h before treatment and impedance was continuously measured
until the end of the treatment. Standard deviations of well replicates were analyzed
with the RTCA Software.
Statistical analysis
Relative values were compared to the value of the control condition (100 or 1)
by a one-sample Student’s t test. Groups for Real-Time Cell Analysis were compared
using a two-sample Student’s t test. Bilateral alpha risk was set to 0.05 for each sta-
tistical test.
Results
BEZ235 inhibits PI3K/Akt/mTOR pathway activation in platinum-
resistant SKOV3 and IGROV1-R10 ovarian cancer cell lines
We ﬁrst analyzed the activation status of the PI3K/Akt/mTOR
pathway in SKOV3 and IGROV1-R10 cisplatin-resistant ovarian
carcinoma cell lines. This was achieved by studying the phosphor-
ylation of Akt residues governed by PI3K-initiated events (Thr308)
or by mTORC2 (Ser473) and the phosphorylation of mTORC1 tar-
gets p70S6K (Thr389) and 4E-BP1 (Thr70). Our results showed that
both cell lines displayed activation of Akt, p70S6K and 4E-BP1
(Fig. 1A) and that these activations were stronger in the IGROV1-
R10 cell line than in the SKOV3.
We then investigated the impact of a range of concentrations of
BEZ235 on PI3K/Akt/mTOR pathway activation in our cell lines.
BEZ235 at concentrations of 250 nM or higher efﬁciently inhibited
the phosphorylation of Akt on Ser473 and Thr308 in both cell lines(Fig. 1B). Furthermore, a strong inhibition of p70S6K and 4E-BP1
phosphorylation was observed at concentrations higher than or
equal to 100 nM. We chose to restrict our study to the higher
BEZ235 concentrations (250 nM and 1000 nM), 1000 nM being
the only concentration that allowed a drastic inhibition of the
phosphorylation of all the considered direct or indirect targets of
PI3K, mTORC1 and mTORC2.
BEZ235 inhibits proliferation of SKOV3 and IGROV1-R10 cell lines
without inducing apoptosis
We then explored the effect of BEZ235 on proliferation and
induction of apoptosis in SKOV3 and IGROV1-R10 cell lines.
250 nM and 1000 nM of BEZ235 exerted a strong and persistent
cytostatic effect in both cell lines (Fig. 2A). The analysis of DNA
content histograms revealed that a 24 h-exposure to BEZ235 elic-
ited a massive blockade of both cell lines in the G0/G1 phases;
81% of events for SKOV3 cells treated with 1000 nM BEZ235 versus
63% with DMSO control (Fig. 2B, left panel), and 76% of events for
IGROV1-R10 cells treated with 1000 nM BEZ235 versus 54% with
DMSO (Fig. 2B, right panel). However, 250 nM and 1000 nM
BEZ235 did not induce apoptosis in either cell line, as suggested
by the absence of cell detachment, sub-G1 fraction on DNA histo-
grams, nuclear condensation and fragmentation (Fig. 2B) and of
PARP and caspase 3 cleavages, even after 72 h (Fig. 2C).
BEZ235 modulates the expression of Mcl-1 and its pro-apoptotic
partners in SKOV3 and IGROV1-R10 cell lines
We then studied the expression of Mcl-1, Bcl-xL and Bcl-2 anti-
apoptotic proteins and that of the BH3-only proteins Bim, Puma
and Noxa in response to a 24 h treatment with BEZ235. Compared
to control, Mcl-1 protein expression reduced by around 50% in re-
sponse to 250 nM and 1000 nM BEZ235 in both SKOV3 and
IGROV1-R10 cell lines (Fig. 3A and B). BEZ235 treatment affected
neither Bcl-xL nor Bcl-2 expression levels (Bcl-2 is not expressed
in IGROV1-R10, Fig. 3A). Interestingly, BEZ235 induced a dose-
dependent increase in Bim protein expression in IGROV1-R10 cells
(2.2-fold increase in response to 1000 nM BEZ235 as compared to
control, Fig. 3A and B). In SKOV3 cells, the level of Bim protein
was very low and remained unchanged in response to treatment.
However, BEZ235 triggered an upregulation of Bim mRNA in both
cell lines (1.8-fold increase in response to 1000 nM BEZ235 as com-
pared to control in SKOV3 cells and a 2.3-fold increase in response
to 1000 nM BEZ235 as compared to control in IGROV1-R10 cells,
Fig. 3C), although the basal Bim mRNA level was approximately
3-fold lower in the SKOV3 cell line as compared to the IGROV1-
R10 cell line. Concerning Puma protein expression, it was dose-
dependently upregulated by BEZ235 treatment in both cell lines,
the upregulation being even stronger in the SKOV3 cell line
(11.3-fold increase in response to 1000 nM BEZ235 as compared
to control, Fig. 3A) than in the IGROV1-R10 cell line (2.2-fold in-
crease in response to 1000 nM BEZ235 as compared to control,
Fig. 3A). Finally, the expression of Noxa appeared to be on the con-
trary downregulated in response to treatment (Fig. 3A).
Combining BEZ235 with inhibition of Bcl-xL expression or activity
induces massive cell death in the IGROV1-R10 cell line
We ﬁrst evaluated the impact of combining BEZ235 treatment
with the siRNA-induced inhibition of Bcl-xL expression. IGROV1-
R10 cells were transfected with Bcl-xL siRNA and treated 48 h later
with BEZ235 for 24 h. This protocol was designed to ensure that
optimal siRNA-mediated inhibition of Bcl-xL (observed 72 h after
transfection, Fig. 4A) coincided with optimal BEZ235-induced inhi-
bition of Mcl-1 and upregulation of Bim and Puma. Coupling
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Fig. 1. BEZ235 inhibits PI3K/Akt/mTOR pathway activation in platinum-resistant SKOV3 and IGROV1-R10 ovarian cancer cell lines. Analysis of PI3K/Akt/mTOR pathway
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as shown by the strong cell detachment, the emergence of a sub-
G1 peak on DNA histograms (60% of events), the observation of
condensed and fragmented nuclei (Fig. 4B) and the cleavage of
both PARP and caspase 3 (Fig. 4C). On the contrary, combining
BEZ235 with control siRNA was not cytotoxic (Fig. 4B and C).
Real-time cell analysis (xCELLigence RTCA technology) also con-
ﬁrmed the cytotoxic effect of the siBcl-xL/BEZ235 combination
(Fig. 4D). Indeed, a dramatic drop in the cell index occurred follow-
ing transfection of the cells with siBcl-xL and their treatment with
BEZ235. This was in contrast to the growth stagnation elicited by
siBcl-xL transfection alone or the only slight decrease in cell index
observed following transfection of siCtrl combined with BEZ235
treatment.
We next associated BEZ235 treatment with inhibition of Bcl-xL
activity using the BH3-mimetic molecule ABT-737 in the IGROV1-
R10 cell line. As the modulation of Mcl-1, Bim and Puma protein
expression by BEZ235 is supposed to occur more slowly than the
inhibition of Bcl-xL activity by ABT-737, ABT-737 (5 lM) was
added 24 h after BEZ235 treatment, when both the inhibition of
Mcl-1 and the upregulation of Bim and Puma were optimal.Analysis was performed 24 h later. Alone, ABT-737 elicited no sig-
niﬁcant apoptosis (Fig. 4E) but when combined with BEZ235, it in-
duced massive cell death as demonstrated by the presence of cell
detachment, a sub-G1 fraction on DNA histograms (56% of events,
Fig. 4E, left panel) and the detection of PARP and caspase 3 cleaved
forms (Fig. 4E, right panel).
We next investigated whether the BEZ235-induced upregula-
tions of Bim and Puma were involved in the apoptotic cell death
in response to the BEZ235/ABT-737 combination. We silenced
Bim or Puma expression before exposing cells to the combination
treatment and studied the apoptotic response of cells (Fig. 4F).
Our results showed that silencing Puma did not induce any resis-
tance to the BEZ235/ABT-737 combined treatment, precluding that
the BEZ235-induced upregulation of Puma could be involved in the
observed cell death (Fig. 4F). In contrast, cells transfected with Bim
siRNA displayed a lower level of apoptosis than cells transfected
with control siRNA in response to the combined treatment, high-
lighting a role of Bim in BEZ235/ABT-737-mediated cell death
(Fig. 4F). Immunoprecipitation studies revealed that in BEZ235-
treated cells, overexpressed Bim was strongly trapped and hence
perhaps had its pro-apoptotic role impeded by Bcl-xL (Fig. 4G). This
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context and may suggest again a role of Bim in BEZ235/ABT-737-
mediated apoptosis.
We then evaluated the impact of the BEZ235/ABT-737 combina-
tion in the platinum-sensitive IGROV1 cell line from which the
IGROV1-R10 cell line was established. We ﬁrst veriﬁed that
BEZ235 (1000 nM) efﬁciently inhibited PI3K/Akt/mTOR pathway
activation (Supplementary Fig. 1A), repressed Mcl-1 expression
and induced Bim expression (Supplementary Fig. 1B) in this cell
line. Moreover, we showed that the effect triggered by the
BEZ235/ABT-737 combination in IGROV1 cells was quite similarto the one observed in IGROV1-R10 cells (Supplementary Fig. 1C
and D).
Finally, to exclude that the results obtained with the BEZ235/
ABT-737 combination in IGROV1-R10 cells could be ascribed to
off target effects of BEZ235, we studied the impact of combining
another PI3K/mTOR dual inhibitor, BGT226, with ABT-737. An 8 h
treatment with 250 nM BGT226 alone drastically inhibited PI3K/
Akt/mTOR pathway activation (Supplementary Fig. 2A), reduced
Mcl-1 expression and up-regulated Bim expression (Supplemen-
tary Fig. 2B). As expected, addition of ABT-737 (5 lM) after such
a BGT226 pre-treatment triggered a massive apoptosis in the
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A. Jebahi et al. / Cancer Letters 348 (2014) 38–49 45IGROV1-R10 cell line (Supplementary Fig. 2C–D), suggesting that
the results obtained with BEZ235 could be extended to other
PI3K/mTOR dual inhibitors.Combining BEZ235 with CI-1040-induced Bim expression sensitizes
the SKOV3 cell line to ABT-737
We next investigated the combination of BEZ235 with either
Bcl-xL siRNA transfection (Fig. 5A) or ABT-737 (Fig. 5B) in the
SKOV3 cell line and showed that neither of these strategies was
effective. As described above, BEZ235 treatment repressed Mcl-1
protein expression and induced Puma protein expression but it
did not promote Bim protein expression in the SKOV3 cell line, in
contrast to that observed in the IGROV1-R10 cell line (Fig. 3A
and B). Based on these ﬁndings, we hypothesized that the inefﬁ-
cacy of the combined treatment in SKOV3 cell line could be as-
cribed to failure of BEZ235 to induce Bim. As Bim can be
phosphorylated by ERK1/2 on serine 69, resulting in its proteaso-
mal degradation [41], we investigated the level of ERK1/2 phos-
phorylation (Thr202/Tyr204) in SKOV3 cells as compared to
IGROV1-R10 cells. ERK1/2 activation was 3-fold stronger in the
SKOV3 cell line than in the IGROV1-R10 cell line (Fig. 5C, upper pa-
nel). Moreover, the high level of ERK1/2 phosphorylation was not
modiﬁed in response to BEZ235 treatment in SKOV3 cells
(Fig. 5C, lower panel). These results could explain the low level
of Bim expression observed in SKOV3 cell line both at the basal le-
vel and in response to BEZ235. The treatment of SKOV3 cells with
CI-1040 MEK inhibitor, which drastically abrogated ERK1/2 phos-
phorylation, efﬁciently upregulated the expression of Bim
(Fig. 5C, lower panel). Moreover, this protein appeared in its
dephosphorylated form, as demonstrated by the shift of the corre-
sponding band (Fig. 5C, lower panel). This CI-1040-induced Bim
expression was further increased by BEZ235 (Fig. 5C, lower panel).
Otherwise, CI-1040 modiﬁed Puma expression neither at basal
state nor in response to BEZ235 (Fig. 5C, lower panel). We then
studied whether restoration of Bim expression in the SKOV3 cell
line could confer sensitivity to ABT-737/BEZ235 treatment. Indeed,
CI-1040 coupled with BEZ235 sensitized the SKOV3 cell line to
ABT-737 (Fig. 5D); while BEZ235/CI-1040 treatment alone did
not display any toxicity, its combination with ABT-737 induced a
massive apoptosis in the SKOV3 cell line, as demonstrated by mor-
phological features of the cell layers, sub-G1 peak (52% of events,
Fig. 5D, left panel) and PARP and caspase 3 cleavages (Fig. 5D, right
panel). Similar results were obtained when BEZ235 was replaced
by BGT226 (Supplementary Fig. 3A–D). Interestingly, transfection
of SKOV3 cells with Bim siRNA partially protected SKOV3 cells
against BEZ235/CI-1040/ABT-737-induced apoptosis, suggesting
that the observed effect of ERK inhibition on the apoptotic re-
sponse to BEZ235/ABT-737 was dependent on Bim (Fig. 5E). More-
over, silencing Puma also induced some resistance to the combined
treatment, implying that Puma upregulated by BEZ235 was in-
volved in the observed apoptosis. Finally, the inhibition of both
Bim and Puma expressions strengthened the resistance observed
when Bim or Puma were inhibited separately (Fig. 5E).Discussion
The poor outcome of patients diagnosed with ovarian carci-
noma and treated with conventional chemotherapy emphasizes
the urgent need to develop innovative therapies. In a previous
study, we demonstrated that targeting both Bcl-xL and Mcl-1 by
a siRNA approach efﬁciently eradicated ovarian carcinoma cells
[4]. The objective of the present work was to assess the efﬁcacy
of a strategy combining Bcl-xL inhibition by the BH3-mimetic mol-
ecule ABT-737 and Mcl-1 inhibition by pharmacological disruptionof the PI3K/Akt/mTOR pathway upstream using BEZ235 in plati-
num-refractory cancer cell lines.
We have ﬁrstly conﬁrmed that BEZ235 efﬁciently inhibits PI3K,
mTORC1 and mTORC2 activity in our preclinical models of ovarian
cancer. Indeed, it triggered dephosphorylation of mTORC1 targets
4E-BP1 and p70S6K and dephosphorylation of Akt both on the site
targeted by mTORC2 (Ser473) and on the site targeted by PDK1 fol-
lowing PI3K activation (Thr308). Moreover, BEZ235 inhibited cell
proliferation by eliciting a blockade in G0/G1 phases of IGROV1-
R10 and SKOV3 cell lines. This underlines the dependency of ovar-
ian cancer cell proliferation on the PI3K/Akt/mTOR pathway and
conﬁrms data in the literature showing that BEZ235 represses pro-
liferation in ovarian cancer cells [37,38], as well as in other cancer
cell types [32–36].
Our results also highlight for the ﬁrst time that BEZ235 de-
creases Mcl-1 protein expression in ovarian cancer cells. Dual inhi-
bition of PI3K and mTOR by BEZ235 has been described to
downregulate Mcl-1 expression in other tumour cell types such
as myeloid leukaemia cells [29], various lymphoma cells [36,42]
and EGFR-mutant lung cancer cells [43]. Mcl-1 can be in particular
antagonized by the BH3-only proteins Bim and Puma. Our study
ﬁrst pointed out that BEZ235 upregulated Puma expression in
ovarian cancer cell lines, as reported in other cell types
[36,42,44]. In contrast to Mcl-1 and Puma, Bim protein was consis-
tently differentially modulated by BEZ235 in the SKOV3 and
IGROV1-R10 cell lines. In IGROV1-R10 cells, the dual inhibitor
upregulated the expression of Bim protein, as described in other
cell types [36,45], and also the expression of Bim mRNA. However,
in SKOV3 cells, the basal protein expression level of Bim appeared
very low and was not increased by BEZ235, as has previously been
reported in HER2-ampliﬁed breast and EGFR-mutant lung cancer
cell lines [43,44], despite an increase in the level of Bim mRNA.
We therefore hypothesized that the low basal expression of Bim
protein found in the SKOV3 cell line could result from a high rate
of protein degradation. Bim can be phosphorylated by ERK1/2,
which primes it for ubiquitination and proteasomal degradation
[41]. In agreement with this, low protein levels of Bim correlated
with high levels of P-ERK1/2 in SKOV3 cells, both in the basal state
and in response to BEZ235. As a comparison, the basal P-ERK/ERK
ratio in SKOV3 cells was 3-fold higher than that observed in
IGROV1-R10 cells, which expressed high levels of Bim. Our results
corroborate with those of a previous study showing that the SKOV3
cell line displays a high level of ERK activation associated with very
high expression levels of EGFR and HER2 proteins upstream [46].
Finally, disrupting ERK1/2 phosphorylation using the CI-1040
MEK inhibitor allowed the induction of Bim protein in a dephos-
phorylated form, providing further evidence to implicate P-ERK1/
2 in the low Bim protein expression in the SKOV3 cell line.
In the IGROV1-R10 cell line, treatment with BEZ235 did not eli-
cit apoptosis, in spite of Mcl-1 downregulation and Bim and Puma
upregulations. Bcl-xL anti-apoptotic protein, the expression of
which remained high in response to BEZ235 treatment, could be
responsible for this cell survival. Indeed, previous results of our
team highlighted that concomitant inhibition of Bcl-xL and Mcl-1
was necessary to eradicate resistant ovarian carcinoma cells [4–
6]. Moreover, our present ﬁndings show that Bcl-xL trapped
BEZ235-induced upregulated Bim, thereby precluding its activity
either as an inhibitor of residual Mcl-1 or as an activator of multi-
domain pro-apoptotic proteins. Interestingly and as hypothesized,
our results demonstrate that combining Bcl-xL inhibiting strategies
with BEZ235-induced inhibition of Mcl-1 expression efﬁciently
eradicated IGROV1-R10 cells. Similar results were obtained using
another PI3K/mTOR dual inhibitor, BGT226, which further vali-
dated our ﬁndings. The apoptotic cell death in response to
BEZ235/ABT-737 treatment was partly dependent on BEZ235-in-
duced Bim upregulation as silencing of Bim rendered cells partially
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A. Jebahi et al. / Cancer Letters 348 (2014) 38–49 47resistant to apoptosis in response to the combined treatment. On
the contrary, BEZ235-induced Puma upregulation did not seem
to play a role in the observed cell death. The strategy of combining
BEZ235 and ABT-737 (or ABT-263) has also recently proved to be
efﬁcient against haematological cancer cells and, as suggested by
our results, the Bim/Mcl-1 ratio appeared as a major determinant
of the response to the combined treatment. Indeed, in myeloid leu-
kaemia cells, the BEZ235-induced Mcl-1 downregulation was
shown to contribute towards the BEZ235/ABT-737 lethality in a
Bim-dependent manner [29]. In lymphoma cells, BEZ235 increased
Bim and Puma expression in all studied cell lines, whereas BEZ235-
mediated Mcl-1 downregulation was cell line dependent. Coupling
BEZ235 with ABT-263 had a signiﬁcant combinative effect only in
the cell lines in which BEZ235 succeeded in downregulating Mcl-1
expression [36]. Elsewhere, in ovarian cancer cells cultured as 3D
spheroids in reconstituted basement membrane, BEZ235/ABT-737
treatment induced spheroid disintegration [47]. In this study, the
ABT-737 was used to bypass matrix-associated resistance medi-
ated by BEZ235-induced Bcl-2 upregulation, however Mcl-1
expression and its role in the response to BEZ235 was not
investigated.
However, in SKOV3 cells that expressed very low levels of Bim
(both at basal state and in response to BEZ235), BEZ235 did not
efﬁciently sensitize cells to Bcl-xL-targeting strategies, although it
did downregulate Mcl-1 expression and upregulate Puma expres-
sion. We postulated that inefﬁcacy of this strategy could be as-
cribed to a low Bim expression level. We therefore used the MEK
inhibitor CI-1040 to restore Bim expression and so attempted to
trigger apoptosis with the BEZ235/ABT-737 combined treatment.
The BEZ235/CI-1040/ABT-737 triple combination was indeed very
efﬁcient to eradicate SKOV3 cells. To our knowledge, only one
study has explored the anticancer potential of a similar strategy,
combining Navitoclax with both a PI3K and a MEK inhibitor in
non-small cell lung cancer cell lines and pancreatic ductal adeno-
carcinoma derived cell lines [48]. Moreover, our results emphasize
that CI-1040-induced Bim is involved in the apoptosis of SKOV3
cells, again underlining the role of Bim in the apoptosis occurring
in response to the BEZ235/ABT-737 combination. Interestingly,
BEZ235-induced Puma upregulation also contributes to the apop-
tosis in response to the BEZ235/CI-1040/ABT-737 combination, in
contrast to what was described in IGROV1-R10 cells in response
to the BEZ235/ABT-737 combination. It can be assumed that in
the SKOV3 cell line that displays a very low level of Bim, the role
of Puma is strengthened. In tyrosine kinase inhibitor-resistant lung
and breast cancer cell lines that expressed low levels of Bim, it was
reported that BEZ235-induced Puma expression was sufﬁcient to
sensitize to ABT-737 treatment [44]. In SKOV3 cells, Bim and Puma
appeared to cooperate to induce cell death in response to BEZ235/
CI-1040/ABT-737 treatment as inhibiting both Bim and Puma in-
duced a stronger resistance than silencing each of these proteins
separately. Otherwise, apart from BEZ235/CI-1040/ABT-737 com-
bination, none of the tested double combinations were efﬁcient
to eradicate SKOV3 cells. Our results thus demonstrated that cou-
pling CI-1040 with ABT-737 was not cytotoxic in the SKOV3 cell
line, contrarily to that reported in B-Raf and K-Ras mutant carci-
noma cells [49–51] and in acute myeloid leukaemia cells [19]. Else-
where, ERK1/2-mediated phosphorylation of Bim has been shown
to promote its rapid dissociation from Mcl-1 and Bcl-xL [52]. It is
conceivable therefore that in the SKOV3 cell line, CI-1040-medi-
ated dephosphorylation of Bim should result in Bim binding to
Mcl-1 and Bcl-xL. ABT-737 may disrupt Bcl-xL binding to Bim but
the released Bim may be insufﬁcient to efﬁciently inhibit Mcl-1
and/or to activate pro-apoptotic multidomain proteins Bax and
Bak. Our results obtained in the SKOV3 cell line in response to
BEZ235/ABT-737 and CI-1040/ABT-737 combinations altogetherindicate the importance of considering the ratio between Mcl-1
and its BH3-only partners rather than the expression of each of
them alone when elaborating ABT-737-sensitizing strategies. Our
data ﬁnally show that concomitant inhibition of PI3K/Akt/mTOR
and MEK/ERK pathways does not elicit apoptosis in SKOV3 cells,
contrarily to ﬁndings in other cellular models [43,53]. Thus, down-
regulation of Mcl-1 (promoted by BEZ235) and upregulation of Bim
and Puma (promoted by CI-1040 and BEZ235 respectively) were
not sufﬁcient to break the antiapoptotic/proapoptotic rheostat
and to commit cells to apoptosis in this model, likely due to Bim
and Puma trapping by Bcl-xL.
To conclude, whereas BEZ235 did not exert a cytotoxic effect on
its own, it interestingly modulated the expression of Bcl-2 family
proteins. In particular, BEZ235 induced a strong increase in the
Bim/Mcl-1 ratio that makes it an attractive sensitizer to BH3-mi-
metic molecules such as ABT-737 or ABT-263. Our study has thus
highlighted for the ﬁrst time that combining Bcl-xL-inhibiting
strategies with BEZ235-induced inhibition of Mcl-1 expression is
a powerful strategy to eradicate ovarian cancer cell lines, provided
that Bim is highly expressed in response to BEZ235. We have also
provided several arguments favouring the role of Bim in BEZ235/
ABT-737-induced cell death in our models. First, BEZ235/ABT-737
selectively elicited apoptosis in the IGROV1-R10 cell line in which
Bim was upregulated by BEZ235, and not in the SKOV3 cell line in
which Bim expression remained very low. Secondly, the MEK
inhibitor CI-1040 upregulated Bim expression in SKOV3 cells and
sensitized them to BEZ235/ABT-737-mediated lethality. Finally,
silencing Bim expression elicited some resistance to BEZ235/ABT-
737 treatment in IGROV1-R10 cells and to BEZ235/CI-1040/ABT-
737 treatment in SKOV3 cells. Otherwise, our study has pointed
out that in the SKOV3 cell line that displays a low level of Bim
expression, BEZ235-induced Puma is also involved in the apoptosis
triggered by the combined treatment. The concept of co-chemo-
sensitization between BEZ235 and ABT-737 supported by our re-
sults is particularly attractive considering the potential clinical
use of these two innovative molecules in chemoresistant ovarian
carcinomas. Moreover, this work allows us to propose pharmaco-
logical inhibition of the ERK1/2 pathway as an original approach
to sensitize low Bim-expressing tumours to the BEZ235/ABT-737
combination. These concepts are in keeping with mounting evi-
dence in favour of the requirement for multi-targeting strategies
to efﬁciently disrupt cancer cell survival networks.Conﬂict of Interest
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